UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
Amendment No. 1
|
X
|
QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015
|
|
__
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the transition period from _________________ to __________________
Commission File Number: 000-54905
Cantabio Pharmaceuticals Inc.
(Exact name of registrant as specified in its charter)
|
Delaware
|
000-54905
|
99-0373067
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
2225 East Bayshore Road #223
Palo Alto, California
(Address of principal executive offices)
|
94303
(Zip Code)
|
(650)320-1765
Registrant’s telephone number, including area code
N/A
(Former name or former address, if changed since last report)
Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. X Yes oNo
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). X Yes oNo
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer
|
o
|
Accelerated filer
|
o
|
|
|
Non-accelerated filer
|
o
|
(Do not check if a smaller reporting company)
|
Smaller reporting company
|
X
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). X Yes oNo
As of November 13, 2015, there were 27,250,000 shares of the issuer’s common stock issued and outstanding.
Explanatory Note
We are filing this Amendment No. 1 (the “Amendment”) on Form 10-Q/A to amend our Quarterly Report on Form 10-Q for the three months ended September 30, 2015 (the “Original Filing”) that was filed with the Securities and Exchange Commission on November 23, 2015, solely for the purpose of furnishing Exhibit 101 – Interactive Data File (XBRL Exhibit) required by Rule 405 of Regulation S-T, which was not included with the Original Filing.
The Company is filing Exhibit 101 in accordance with the temporary hardship exemption provided by Rule 201 of Regulation S-T, which extended the date by which the interactive data file is required to be submitted by six business days.
Except as described above, this Amendment No. 1 does not amend any other information set forth in the Original Filing, and the Company has not updated disclosures included therein to reflect any events that occurred subsequent to November 23, 2015.
Item 6. Exhibits
|
31.1
|
Certification of Principal Executive Officer and Acting Principal Accounting Officer pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934 (1)
|
|
31.2
|
Certification of Chief Financial Officer (1)
|
|
32.1
|
Certification of Principal Executive Officer and Acting Principal Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (1)
|
|
32.2
|
Certification Pursuant to Section 906 of the Sarbanes-Oxley Act Of 2002 (1)
|
Pursuant to Rule 406T of Regulation S-T, the interactive data files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.
Exhibit 101
101.INS - XBRL Instance Document (2)
101.SCH - XBRL Taxonomy Extension Schema Document (2)
101.CAL - XBRL Taxonomy Extension Calculation Linkbase Document (2)
101.DEF - XBRL Taxonomy Extension Definition Linkbase Document (2)
101.LAB - XBRL Taxonomy Extension Label Linkbase Document (2)
101.PRE - XBRL Taxonomy Extension Presentation Linkbase Document (2)
|
|
(1)
|
Filed as an exhibit to the Original Filing
|
|
(2)
|
Filed herewith
|
SIGNATURES
In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Cantabio Pharmaceuticals Inc.
By: /s/ Gergely Toth
Gergely Toth
Its: President, Chief Executive Officer, Director (Principal Executive Officer).
November 30, 2015
By: /s/ Simon Peace
Simon Peace
Its: Chief Financial Officer, Director (Principal Accounting Officer)
November 30, 2015
By: /s/ Thomas Roger Sawyer
Thomas Roger Sawyer
Its: Chief Operations Officer, Director
November 30, 2015